241 related articles for article (PubMed ID: 34130197)
1. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
Capone F; Motolese F; Luce T; Rossi M; Magliozzi A; Di Lazzaro V
Mult Scler Relat Disord; 2021 Feb; 48():102734. PubMed ID: 33429305
[TBL] [Abstract][Full Text] [Related]
3. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
[TBL] [Abstract][Full Text] [Related]
4. Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide.
Yetkin MF; Yetkin NA; Akcakoyunlu M; Mirza M
Neurol Sci; 2021 May; 42(5):1661-1664. PubMed ID: 33534122
[TBL] [Abstract][Full Text] [Related]
5. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
Mantero V; Baroncini D; Balgera R; Guaschino C; Basilico P; Annovazzi P; Zaffaroni M; Salmaggi A; Cordano C
J Neurol; 2021 Jun; 268(6):2029-2030. PubMed ID: 32865629
[No Abstract] [Full Text] [Related]
6. Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
Lorefice L; Pilotto S; Fenu G; Cimino P; Firinu D; Frau J; Murgia F; Coghe G; Cocco E
J Neurol Sci; 2022 Jul; 438():120292. PubMed ID: 35605316
[TBL] [Abstract][Full Text] [Related]
7. Rebound syndrome in two cases of MS patients after teriflunomide cessation.
Labauge P; Ayrignac X; Prin P; Charif M; Carra-Dalliere C
Acta Neurol Belg; 2022 Oct; 122(5):1381-1384. PubMed ID: 35802339
[No Abstract] [Full Text] [Related]
8. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
[TBL] [Abstract][Full Text] [Related]
12. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
[TBL] [Abstract][Full Text] [Related]
13. Teriflunomide: Pediatric First Approval.
Paik J
Paediatr Drugs; 2021 Nov; 23(6):609-613. PubMed ID: 34595696
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
[TBL] [Abstract][Full Text] [Related]
15. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
16. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
19. Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?
Pourcher V; Yeung J; Le Pimpec-Barthes F; Maillart E; Gibault L; Boussouar S
Rev Neurol (Paris); 2022 Mar; 178(3):266-267. PubMed ID: 34579947
[No Abstract] [Full Text] [Related]
20. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
